MRI in preclinical drug development.
暂无分享,去创建一个
[1] Graham J. Galloway,et al. Repeated Three-Dimensional Magnetic Resonance Imaging of Atherosclerosis Development in Innominate Arteries of Low-Density Lipoprotein Receptor-Knockout Mice , 2002, Circulation.
[2] S. Sarkar,et al. Disease-modifying activity of SB 273005, an orally active, nonpeptide αvβ3 (vitronectin receptor) antagonist, in rat adjuvant-induced arthritis , 2001 .
[3] Sheng-Kwei Song,et al. Improved magnetic resonance imaging detection of prostate cancer in a transgenic mouse model. , 2002, Cancer research.
[4] M. Fisher,et al. The penumbra, therapeutic time window and acute ischaemic stroke. , 1995, Bailliere's clinical neurology.
[5] T. Nelson,et al. The effect of dexamethasone on tissue water distribution and proton relaxation in Panc02 tumors. , 1987, Magnetic resonance imaging.
[6] Ryuji Hata,et al. A Reproducible Model of Middle Cerebral Artery Occlusion in Mice: Hemodynamic, Biochemical, and Magnetic Resonance Imaging , 1998, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.
[7] M E Moseley,et al. Perfusion and diffusion MR imaging of thromboembolic stroke , 1993, Journal of magnetic resonance imaging : JMRI.
[8] J. Kucharczyk,et al. Nicardipine reduces ischemic brain injury. Magnetic resonance imaging/spectroscopy study in cats. , 1989, Stroke.
[9] M. Rudin,et al. Calcium antagonists reduce the extent of infarction in rat middle cerebral artery occlusion model as determined by quantitative magnetic resonance imaging. , 1986, Stroke.
[10] Toyoki Mori,et al. Cilostazol reduces brain lesion induced by focal cerebral ischemia in rats—an MRI study , 2003, Brain Research.
[11] G. Fagg,et al. Differing effects of α-difluoromethylornithine and CGP 40116 on polyamine levels and infarct volume in a rat model of focal cerebral ischaemia , 1992, Neuroscience Letters.
[12] J. Hennig,et al. PTK787/ZK 222584, a specific vascular endothelial growth factor-receptor tyrosine kinase inhibitor, affects the anatomy of the tumor vascular bed and the functional vascular properties as detected by dynamic enhanced magnetic resonance imaging. , 2002, Cancer research.
[13] R. Coatney,et al. Eprosartan reduces cardiac hypertrophy, protects heart and kidney, and prevents early mortality in severely hypertensive stroke-prone rats. , 2001, Cardiovascular research.
[14] Steven C. R. Williams,et al. The neuronal nitric oxide synthase inhibitor, TRIM, as a neuroprotective agent: effects in models of cerebral ischaemia using histological and magnetic resonance imaging techniques , 2003, Brain Research.
[15] Steven C. R. Williams,et al. Neuroprotection in Ischemia–Reperfusion Injury: An Antiinflammatory Approach Using a Novel Broad-Spectrum Chemokine Inhibitor , 2001, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.
[16] N C Huang,et al. The evolution of acute stroke recorded by multimodal magnetic resonance imaging. , 1993, Magnetic resonance imaging.
[17] R. W. Hansen,et al. The price of innovation: new estimates of drug development costs. , 2003, Journal of health economics.
[18] R. Weissleder. Scaling down imaging: molecular mapping of cancer in mice , 2002, Nature Reviews Cancer.
[19] M Chopp,et al. Diffusion-, T2-, and Perfusion-Weighted Nuclear Magnetic Resonance Imaging of Middle Cerebral Artery Embolic Stroke and Recombinant Tissue Plasminogen Activator Intervention in the Rat , 1998, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.
[20] Z. Bhujwalla,et al. 1H NMR spectroscopy of subcutaneous tumors in mice: Preliminary studies of effects of growth, chemotherapy and blood flow reduction , 1992, NMR in biomedicine.
[21] J. Kucharczyk,et al. NG-nitro-L-arginine delays the development of brain injury during focal ischemia in rats. , 1995, Stroke.
[22] J. Fozard,et al. Pulmonary edema induced by allergen challenge in the rat: Noninvasive assessment by magnetic resonance imaging , 2001, Magnetic resonance in medicine.
[23] Yoji Yoshida,et al. Experimental studies of ischemic brain edema , 1986 .
[24] G. Schlaug,et al. Enlargement of human cerebral ischemic lesion volumes measured by diffusion‐weighted magnetic resonance imaging , 1997, Annals of neurology.
[25] P. Bendel,et al. In vivo studies by magnetic resonance imaging and spectroscopy of the response to tamoxifen of MCF7 human breast cancer implanted in nude mice. , 1991, Cancer communications.
[26] L. Pitts,et al. Magnetic resonance imaging in the evaluation of nimodipine-treated acute experimental focal cerebral ischemia. , 1986, Acta radiologica. Supplementum.
[27] J. Cohn,et al. Angiotensin-converting enzyme inhibition and beta-adrenoceptor blockade regress established ventricular remodeling in a canine model of discrete myocardial damage. , 1994, Journal of the American College of Cardiology.
[28] Vasilis Ntziachristos,et al. High throughput magnetic resonance imaging for evaluating targeted nanoparticle probes. , 2002, Bioconjugate chemistry.
[29] J. Boehm,et al. Disease-modifying activity of SB 242235, a selective inhibitor of p38 mitogen-activated protein kinase, in rat adjuvant-induced arthritis. , 2000, Arthritis and rheumatism.
[30] T. Kent,et al. Effect of NGF treatment on outcome measures in a rat model of middle cerebral artery occlusion , 1999, Journal of neuroscience research.
[31] M. Rudin,et al. Quantitative magnetic resonance imaging of estradiol‐induced pituitary hyperplasia in rats , 1988, Magnetic resonance in medicine.
[32] R. Hof,et al. Effect of Spirapril on Left Ventricular Hypertrophy Due to Volume Overload in Rats , 1992, Journal of cardiovascular pharmacology.
[33] G. Albers,et al. Expanding the window for thrombolytic therapy in acute stroke. The potential role of acute MRI for patient selection. , 1999, Stroke.
[34] G. Steinberg,et al. SNX-111, a novel, presynaptic N-type calcium channel antagonist, is neuroprotective against focal cerebral ischemia in rabbits , 1997, Journal of the Neurological Sciences.
[35] A. Reggiani,et al. The neuroprotective activity of the glycine receptor antagonist GV150526: an in vivo study by magnetic resonance imaging. , 2001, European journal of pharmacology.
[36] B. Roth,et al. Novel Diketopiperazine Enhances Motor and Cognitive Recovery after Traumatic Brain Injury in Rats and Shows Neuroprotection In Vitro and In Vivo , 2003, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.
[37] Anna Moore,et al. In vivo magnetic resonance imaging of transgene expression , 2000, Nature Medicine.
[38] D. Gadian,et al. Monitoring the initial expansion of focal ischaemic changes by diffusion‐weighted MRI using a remote controlled method of occlusion , 1994, NMR in biomedicine.
[39] S. Sarkar,et al. Disease-modifying activity of SK&F 106615 in rat adjuvant-induced arthritis. Multiparameter analysis of disease magnetic resonance imaging and bone mineral density measurements. , 1996, Arthritis and rheumatism.
[40] N. Szeverenyi,et al. A quantitative one-dimensional magnetic resonance imaging technique in adjuvant arthritis: the assessment of disease progression and indomethacin efficacy. , 1995, The Journal of rheumatology.
[41] P. Furmanski,et al. 1H-NMR relaxation times and water compartmentalization in experimental tumor models. , 1986, Magnetic resonance imaging.
[42] L Lasagna,et al. Cost of innovation in the pharmaceutical industry. , 1991, Journal of health economics.
[43] T. Reese,et al. Cytoprotection does not preserve brain functionality in rats during the acute post‐stroke phase despite evidence of non‐infarction provided by MRI , 2000, NMR in biomedicine.
[44] J. Waterton,et al. Use of dynamic contrast-enhanced MRI to evaluate acute treatment with ZD6474, a VEGF signalling inhibitor, in PC-3 prostate tumours , 2003, British Journal of Cancer.
[45] I. Namer,et al. Reduction of traumatic brain injury-induced cerebral oedema by a free radical scavenger. , 1996, European journal of pharmacology.
[46] M. Hoehn,et al. Application of magnetic resonance to animal models of cerebral ischemia , 2001, Journal of magnetic resonance imaging : JMRI.
[47] Wei Chen,et al. Effects of pioglitazone on adipose tissue remodeling within the setting of obesity and insulin resistance. , 2001, Diabetes.
[48] R G Blasberg,et al. Noninvasive quantitation of cytosine deaminase transgene expression in human tumor xenografts with in vivo magnetic resonance spectroscopy. , 1999, Proceedings of the National Academy of Sciences of the United States of America.
[49] P. Barker,et al. Tumor trapping of 5-fluorouracil: in vivo 19F NMR spectroscopic pharmacokinetics in tumor-bearing humans and rabbits. , 1990, Proceedings of the National Academy of Sciences of the United States of America.
[50] Christian M. Kerskens,et al. Reperfusion after Thrombolytic Therapy of Embolic Stroke in the Rat: Magnetic Resonance and Biochemical Imaging , 1998, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.
[51] J. Kucharczyk,et al. MR evaluation of calcium entry blockers with putative cerebroprotective effects in acute cerebral ischaemia. , 1990, Acta neurochirurgica. Supplementum.
[52] R. Coatney,et al. Application of serial in vivo magnetic resonance imaging to evaluate the efficacy of endothelin receptor antagonist SB 217242 in the rat carotid artery model of neointima formation. , 1998, Circulation.
[53] C. Sotak,et al. A new method to improve in-bore middle cerebral artery occlusion in rats: demonstration with diffusion- and perfusion-weighted imaging. , 1998, Stroke.
[54] M. Moseley,et al. Time-course and treatment response with SNX-111, an N-type calcium channel blocker, in a rodent model of focal cerebral ischemia using diffusion-weighted MRI , 1996, Brain Research.
[55] M. Rudin,et al. Calcineurin inhibitors FK506 and SDZ ASM 981 alleviate the outcome of focal cerebral ischemic/reperfusion injury. , 1999, The Journal of pharmacology and experimental therapeutics.
[56] S. Cohen,et al. Comparison of the effects of new specific azasteroid inhibitors of steroid 5α‐reductase on canine hyperplastic prostate: Suppression of prostatic DHT correlated with prostate regression , 1995, The Prostate.
[57] N. van Bruggen,et al. VEGF antagonism reduces edema formation and tissue damage after ischemia/reperfusion injury in the mouse brain. , 1999, The Journal of clinical investigation.
[58] V. Kupriyanov,et al. The effects of drugs modulating K+ transport on Rb+ uptake and distribution in pig hearts following regional ischemia: 87Rb MRI study , 2002, NMR in biomedicine.
[59] Fuhai Li,et al. Neuroprotective effects of a novel broad‐spectrum cation channel blocker, LOE 908 MS, on experimental focal ischemia: A multispectral study , 1999, Journal of magnetic resonance imaging : JMRI.
[60] R. Gillies,et al. Applications of magnetic resonance in model systems: tumor biology and physiology. , 2000, Neoplasia.
[61] M. Osteaux,et al. Inhibitory effect of somatostatin analogue RC-160 on the growth of hepatic metastases of colon cancer in rats: a study with magnetic resonance imaging. , 1992, Cancer research.
[62] B D Ross,et al. Magnetic resonance methods for measurement of disease progression in rheumatoid arthritis. , 1993, Magnetic resonance imaging.
[63] L. Hall,et al. Diffusion-Weighted MRI Used to Detect in Vivo Modulation of Cortical Spreading Depression: Comparison of Sumatriptan and Tonabersat , 2001, Experimental Neurology.
[64] Brian Middleton,et al. Dynamic contrast-enhanced MRI of vascular changes induced by the VEGF-signalling inhibitor ZD4190 in human tumour xenografts. , 2003, Magnetic resonance imaging.
[65] M. Rudin,et al. Reduction of neural damage in irreversible cerebral ischemia by calcium antagonists. , 1988, Neurochemical pathology.
[66] J. Mandeville,et al. Neuroprotection with NBQX in rat focal cerebral ischemia. Effects on ADC probability distribution functions and diffusion-perfusion relationships. , 1997, Stroke.
[67] N. Fukunaga,et al. An animal model of cerebral infarction. Homologous blood clot emboli in rats. , 1982, Stroke.
[68] G. Fagg,et al. Characterization of the Cerebroprotective Efficacy of the Competitive NMDA Receptor Antagonist CGP40116 in a Rat Model of Focal Cerebral Ischemia: An in vivo Magnetic Resonance Imaging Study , 1993, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.
[69] P. Hellings,et al. Eosinophilic rhinitis accompanies the development of lower airway inflammation and hyper‐reactivity in sensitized mice exposed to aerosolized allergen , 2001, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.
[70] S. Nerurkar,et al. p38 MAPK Inhibitors Ameliorate Target Organ Damage in Hypertension: Part 2. Improved Renal Function as Assessed by Dynamic Contrast-Enhanced Magnetic Resonance Imaging , 2003, Journal of Pharmacology and Experimental Therapeutics.
[71] J. Fozard,et al. Resolution of the oedema associated with allergic pulmonary inflammation in rats assessed noninvasively by magnetic resonance imaging , 2003, British journal of pharmacology.
[72] J Seega,et al. Diffusion- and T2-weighted imaging: evaluation of oedema reduction in focal cerebral ischaemia by the calcium and serotonin antagonist levemopamil. , 1993, Magnetic resonance imaging.
[73] R. Hargreaves,et al. Clinical biomarkers in drug discovery and development , 2003, Nature Reviews Drug Discovery.
[74] K. Taber,et al. Magnetic resonance imaging of the efficacy of specific inhibition of 5α‐reductase in canine spontaneous benign prostatic hyperplasia , 1991 .
[75] H. Körperich,et al. MRI and MRS studies on the time course of rat brain lesions and the effect of drug treatment: Volume quantification and characterization of tissue heterogeneity by parameter selection , 1993, Magnetic resonance in medicine.
[76] J. Wettstein,et al. In vivo neuroprotective effects of ACEA 1021 confirmed by magnetic resonance imaging in ischemic stroke. , 2003, European journal of pharmacology.
[77] Scott E. Fraser,et al. In vivo visualization of gene expression using magnetic resonance imaging , 2000, Nature Biotechnology.
[78] Jean-Claude Baron,et al. Imaging the ischaemic penumbra , 2004, Current opinion in neurology.
[79] S. Sarkar,et al. Application of magnetic resonance imaging for evaluation of the efficacy of SB 217242 in neointimal formation. , 1998, Journal of cardiovascular pharmacology.
[80] R. Weissleder,et al. Molecular imaging in drug discovery and development , 2003, Nature Reviews Drug Discovery.
[81] K. Yu,et al. Verapamil reduces the size of reperfused ischemically injured myocardium in hypertrophied rat hearts as assessed by magnetic resonance imaging. , 1996, American heart journal.
[82] P R Allegrini,et al. Application of magnetic resonance imaging to the measurement of neurodegeneration in rat brain: MRI data correlate strongly with histology and enzymatic analysis. , 1992, Magnetic resonance imaging.
[83] Tibo Gerriets,et al. The macrosphere model Evaluation of a new stroke model for permanent middle cerebral artery occlusion in rats , 2003, Journal of Neuroscience Methods.
[84] R. Coatney,et al. Use of Diffusion-Weighted MRI and Neurological Deficit Scores to Demonstrate Beneficial Effects of Isradipine in a Rat Model of Focal Ischemia , 1999, Pharmacology.
[85] G. Schneider,et al. Lubeluzole following traumatic brain injury in the rat. , 1999, Journal of Neurotrauma.
[86] M. Chopp,et al. A New Rat Model of Thrombotic Focal Cerebral Ischemia , 1997, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.
[87] N. Beckmann,et al. Effects of Sandimmune neoral on collagen-induced arthritis in DA rats: characterization by high resolution three-dimensional magnetic resonance imaging and by histology. , 1998, Journal of magnetic resonance.
[88] C. Sotak,et al. Glycine site antagonist attenuates infarct size in experimental focal ischemia. Postmortem and diffusion mapping studies. , 1997, Stroke.
[89] G. Sutherland,et al. Effect of U74006F on forebrain ischemia in rats. , 1991, Stroke.
[90] Simon A Roberts. Drug metabolism and pharmacokinetics in drug discovery. , 2003, Current opinion in drug discovery & development.
[91] Maythem Saeed,et al. Noninvasive assessment of the effects of nicorandil on left ventricular volumes and function in reperfused myocardial infarction. , 2002, Cardiovascular research.
[92] Y. Kiyota,et al. Beneficial effect of CV-4151 (Isbogrel), a thromboxane A2 synthase inhibitor, in a rat middle cerebral artery thrombosis model. , 1995, Thrombosis research.
[93] J. Kucharczyk,et al. Hyperglycemia augments ischemic brain injury: in vivo MR imaging/spectroscopic study with nicardipine in cats with occluded middle cerebral arteries. , 1991, AJNR. American journal of neuroradiology.
[94] Fuhai Li,et al. Use of diffusion- and perfusion-weighted magnetic resonance imaging in drug development for ischemic stroke. , 2003, Current drug targets. CNS and neurological disorders.
[95] T. Reese,et al. In vivo magnetic resonance methods in pharmaceutical research: current status and perspectives , 1999, NMR in biomedicine.
[96] T. Kuroiwa,et al. Evolution of cerebral ischaemia induced by thromboembolism in rats detected by early sequential MR imaging. , 2001, British journal of anaesthesia.
[97] G. Steinberg,et al. Correlation of CGS 19755 Neuroprotection against in vitro Excitotoxicity and Focal Cerebral Ischemia , 1995, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.
[98] M. Rudin,et al. From anatomy to the target: Contributions of magnetic resonance imaging to preclinical pharmaceutical research , 2001, The Anatomical record.
[99] S. Whitebread,et al. Left ventricular wall stress and sarcoplasmic reticulum Ca(2+)-ATPase gene expression in renal hypertensive rats: dose-dependent effects of ACE inhibition and AT1-receptor blockade. , 1996, Cardiovascular research.
[100] H. Fujiki,et al. Effects of OPC-18790, a new positive inotropic agent, on energetics in the ischaemic canine heart: a 31P-MRS study. , 1995, Cardiovascular research.